Health Care Roundup: Market Talk
A facts-only brief, written by a local AI model from this article in The Wall Street Journal, October 14, 2026. It may contain mistakes, and it is not the article: the full story is at wsj.com.
Johnson & Johnson reported third-quarter results where its pharmaceutical segment exceeded expectations with a 7.7% sales increase, while its medical device division missed analyst forecasts. According to FactSet, MedTech revenue rose 2.5% to $8.64 billion, falling short of the $8.74 billion estimate. The company attributed most of its overall revenue growth to the Western Hemisphere, with U.S. sales climbing 9.1% and the rest of the region increasing nearly 13%. In contrast, European revenue declined slightly, and Asia-Pacific and African sales rose by 1%.
Background
- Jefferies analyst David Stanton stated that Cochlear’s established clinic relationships should limit near-term disruption from Advanced Bionics’ new Integro CI sound processor, maintaining a hold rating with a target price of 144.75 Australian dollars.
- Bell Potter analyst Martyn Jacobs lowered his fiscal 2026 sales forecast for EBR Systems by 21% to $10.8 million, citing disappointing sales that suggest the wireless pacemaker developer will need additional equity financing after mid-2027.
- Johnson & Johnson’s surgery business was the only MedTech segment to record a sales decline, dropping 0.6% worldwide due to reduced international revenue, while cardiovascular, orthopaedics, and vision businesses grew between 3% and 4.5%.
Read the full article at wsj.com
More from Wednesday, October 14:
1 facts-only AI brief of The Wall Street Journal articles, with links to each.
Briefs for Wednesday, October 14, 2026
Write a comment